| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Interferon alpha/beta receptor 1;IFN-R-1;IFN-alpha/beta receptor 1;Cytokine receptor class-II member 1;Cytokine receptor family 2 member 1;CRF2-1;Type I interferon receptor 1;IFNAR1;IFNAR; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human Interferon Receptor alpha |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-IFNAR1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AF-9; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-Interferon Receptor alpha IFNAR1 Rabbit Monoclonal Antibody catalog # M00306. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: IFNAR1 (Interferon alpha/beta receptor 1).
- Antibody format: Monoclonal; clone AF-9; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
IFNAR1 (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986). Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986). Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta- subunits themselves (PubMed:7665574, PubMed:21854986). Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity). . Reported cellular localization context: Isoform 1: Cell membrane ; Single- pass type I membrane protein . Late endosome . Lysosome . Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes. . Tissue expression notes (as provided): IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN-alpha resistant myeloma cell line U266R. .
Research relevance and current trends
- Research context keywords from the source record include: Cancer,Cytokines,Epigenetics and Nuclear Signaling,Immunology,Innate Immunity,Interferons,Nuclear Signaling,Nuclear Signaling Pathways,Signal Transduction,Signaling Pathway,Tumor Immunology.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate IFNAR1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect IFNAR1 expression by Western blot in cell or tissue lysates, Compare relative IFNAR1 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 62 kDa; calculated MW: 63525 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 62 kDa
- Cellular localization (provided): Isoform 1: Cell membrane ; Single- pass type I membrane protein . Late endosome . Lysosome . Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes. .
- Tissue details (provided): IFN receptors are present in all tissues and even on the surface of most IFN-resistant cells. Isoform 1, isoform 2 and isoform 3 are expressed in the IFN-alpha sensitive myeloma cell line U266B1. Isoform 2 and isoform 3 are expressed in the IFN-alpha resistant myeloma cell line U266R. Isoform 1 is not expressed in IFN-alpha resistant myeloma cell line U266R. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
